MedTrace Logo

Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty

NCT02379663 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 639

Last updated 2015-03-05

No results posted yet for this study

Summary

This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.

Conditions

  • Osteoarthritis, Hip
  • Femur Head Necrosis
  • Femoral Neck Fractures

Interventions

DRUG

Rivaroxaban

Rivaroxaban was taken orally in a dosage of 10mg once daily

DRUG

Enoxaparin

Enoxaparin was injected subcutaneously in a dosage of 40mg once daily

OTHER

Normal saline

subcutaneous injection of 1 cc of normal saline once daily

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02379663 on ClinicalTrials.gov